
CONNIE BRITTON doesn't often hear the word "no." The Emmy-nominated actress and producer has a string of iconic credits, including starring roles in The White Lotus, Friday Night Lights, and Nashville. She's a venture investor, a Dartmouth board member, and a United Nations Goodwill Ambassador.
But the show that her company, Deep Blue Productions, was developing in 2022 wasn't winning over the top brass at a Hollywood studio she pitched.
An intergenerational drama called Hysterical Women, it would center on four women, each experiencing a different hormonal shift. "We've got a daughter who is getting her period, a mother who is perimenopausal, her sister who is trying to go through fertility treatments, and then we've got the grandmother who is through menopause and having the best sex of her life," Britton told an audience of female corporate leaders at the Fortune Most Powerful Women Summit in October. "It's a fantastic show! Who wouldn't watch that show?" The audience laughed and murmured assent.
And yet, Britton told them, Hysterical Women was not greenlit. The reason for this? The studio already had a show "on the air with four women," and executives felt there wasn't the space-or audience appetite-for a second.
The anecdote elicited rueful laughter. Granted, a show about "hysterical," hormonal women might not be for everyone. But Britton's point was clear: Men still run much of Hollywood.
The demoralizing reality, Britton told Fortune in a follow-up interview, is that even now, "there is not as much space for women-run and women-led programming."
هذه القصة مأخوذة من طبعة April - May 2024 من Fortune US.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك ? تسجيل الدخول
هذه القصة مأخوذة من طبعة April - May 2024 من Fortune US.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك? تسجيل الدخول

The Blackstone Edge
90 DAYS. DOZENS OF INTERVIEWS. BILLIONS ON THE LINE. HOW BLACKSTONE'S CEO-MAKER GETS THE JOB DONE.

When Elon Musk has a really tough job, he turns to Steve Davis. DOGE might do the same.
IT WAS THE FALL OF 2022 when employees at Elon Musk's Boring Company began to notice Steve Davis wasn't around.

ASK ANDY - SHOULD MY STARTUP RAISE MONEY FROM VCS? IF SO, WHICH ONES DO I CHOOSE?
A FRIEND—I’ll call him Allen—spent years bootstrapping his real estate enterprise software company. After a long struggle to get to $1 million in sales, his business recently surged to $10 million, and revenue is now growing 100% year on year.

ELLIOTT HILL - JUST DOING IT
Staffers and brand loyalists cheered when Nike's new CEO came out of retirement to lead the company he has had an “irrational love” for since he began there as an intern. Turning it around will take more than good vibes.

HOW TO PLAN YOUR NEXT $100,000 VACATION
ON AN EXCURSION to the ancient city of Petra, Jordan, clients helicoptered in after-hours so they could tour the ruins alone.

THE BATTLE OVER AG1
Influencers are fighting over it. Scientists scoff at it. But the $100-a-month powder once known as Athletic Greens is only getting more popular.

THE WORKPLACE - GEN ZERS WANT TO BE THEIR OWN BOSS.CAN THE CORPORATE WORLD WOO THEM BACK?
CHASE GALLAGHER WAS 12 years old when he started mowing his neighbors' lawns in Chester County, Pa., for $35 a pop in the summer of 2013. At first the Gen Zer had only two customers, but thanks to some aggressive leafleting, he had 10 clients by the following year.

How much can DOGE do?
Elon Musk and Donald Trump aim to cut as much as $2 trillion in federal spending. It'll be even harder than it sounds.

YOUNG PEOPLE ARE DRINKING LESS ALCOHOL. CAN CEO MICHEL DOUKERIS PERSUADE THEM TO KEEP DRINKING AB INBEV'S BEERS?
SOME TIME AGO, top CEOs at an invitation-only seminar at Harvard Business School were asked to imagine the four crises they would likely confront during their tenure at the top: a health emergency, a geopolitical conflict, an economic downturn, and a trade war.

America's drug middlemen are now a $557 billion industry. Can Trump and his allies 'knock out' PBMs?
IN LATE DECEMBER, President-elect Donald Trump put pharmacy benefit managers, or PBMs, on notice.